AI assistant
BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2014
Dec 23, 2014
31868_dirs_2014-12-23_1bfc6027-c18b-4b07-a5a0-f0301e1f1e67.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2014-12-19
Reporting Person: Stonehouse Jon P (Director, President & CEO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-12-19 | Emp. Stock Option (Right to Buy) | $5.45 | A | 25000 | Acquired | 2023-08-08 | Common Stock (25000) | Direct |
Footnotes
F1: On December 19, 2014, the U.S. Food and Drug Administration (FDA) approved RAPIVAB (peramivir injection), an intravenous (i.v.) neuraminidase inhibitor for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in August 2013 has been met. Therefore, 25% of the performance-based stock options vested on December 19, 2014.